small molecule

PHYRAGO

DASATINIB

Loss of exclusivityJanuary 2041latest FDA-listed patent expiry

CompanyHanda Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	PHYRAGO
Active ingredient	DASATINIB
Strength	70MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	December 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12544376	January 2041	use U-3772
11324745	January 2041	use U-3767
11202778	January 2041	use U-3772
12433891	January 2041	use U-3772
11298356	January 2041	product
12465606	January 2041	product

Regulatory exclusivity

Code	Expires
M-307	December 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Handa Pharmaceuticals